{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:29:07Z","timestamp":1768444147153,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00520-023-08223-2","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:03:00Z","timestamp":1702944180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["2023 updated MASCC\/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-1576","authenticated-orcid":false,"given":"Ian","family":"Olver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Clark-Snow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-273X","authenticated-orcid":false,"given":"Christina H.","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-154X","authenticated-orcid":false,"given":"Maria-Angeles","family":"Garcia-del-Barrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-3428","authenticated-orcid":false,"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-3653","authenticated-orcid":false,"given":"Bernardo Leon","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"8223_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1977","unstructured":"Hesketh PJ, Kris KG, Grunberg SM et al (1977) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103\u2013109","journal-title":"J Clin Oncol"},{"issue":"3","key":"8223_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1634\/theoncologist.4-3-191","volume":"4","author":"PJ Hesketh","year":"1999","unstructured":"Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to Clinical practice. Oncologist 4(3):191\u2013196","journal-title":"Oncologist"},{"key":"8223_CR3","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797","journal-title":"J Clin Oncol"},{"key":"8223_CR4","doi-asserted-by":"crossref","unstructured":"Jordan K, Chan A, Gralla R, Jahn F, Rapoport B, Ruhlmann CH, Sayegh P, Hesketh PJ (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents \u2013 Updated MASCC\/ESMO consensus recommendation. Support Care Cancer (in press)","DOI":"10.1007\/s00520-023-08220-5"},{"key":"8223_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T et al (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting. Support Care Cancer 27:87\u201395","journal-title":"Support Care Cancer"},{"key":"8223_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00520-016-3391-z","volume":"25","author":"I Olver","year":"2017","unstructured":"Olver I, Ruhlman C, Jahn F et al (2017) 2016 Updated MASCC\/ESMO consensus recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Support Care Cancer 25:297\u2013301","journal-title":"Support Care Cancer"},{"key":"8223_CR7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71:10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guidelines for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71:10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"8223_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaoncol.2016.2530","volume":"3","author":"W Encinosa","year":"2017","unstructured":"Encinosa W, Davidoff AJ (2017) Changes in antiemetic overuse in response to choosing wisely recommendations. JAMA Oncol 3:320\u2013326","journal-title":"JAMA Oncol"},{"key":"8223_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaoncol.2016.4096","volume":"3","author":"A Okuyama","year":"2017","unstructured":"Okuyama A, Nakamura F, Higashi T (2017) Prescription of prophylactic antiemetic drugs for patients receiving chemotherapy with minimal and low emetic risk. JAMA Oncol 3:344\u2013350","journal-title":"JAMA Oncol"},{"key":"8223_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1078155214524809","volume":"21","author":"F Caracuel","year":"2015","unstructured":"Caracuel F, Mu\u00f1oz N, Ba\u00f1os U, Ramirez G (2015) Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital. J Oncol Pharm Practice 21:163\u2013169","journal-title":"J Oncol Pharm Practice"},{"key":"8223_CR11","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.31557\/APJCP.2020.21.6.1567","volume":"21","author":"M Ebrahimi","year":"2020","unstructured":"Ebrahimi M, Mehrzad V, Moghaddas A (2020) Adherence to ASCO for prophylaxis of acute chemotherapy-induced nausea and vomiting. Asian Pac J Cancer Prev 21:1567\u20131572","journal-title":"Asian Pac J Cancer Prev"},{"key":"8223_CR12","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s13187-020-01689-2","volume":"36","author":"Z Nikbakht","year":"2021","unstructured":"Nikbakht Z, Rajabi M, Shahrasbi A, Roohi E, Hashemian F (2021) Evaluation of adherence to antiemetic treatment guidelines in patients with chemotherapy-induced nausea and vomiting in teaching hospitals in Iran. J Canc Edu 36:1022\u20131029","journal-title":"J Canc Edu"},{"issue":"14","key":"8223_CR13","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1002\/cam4.2486","volume":"8","author":"S Bun","year":"2019","unstructured":"Bun S, Kunisawa S, Sasaki N et al (2019) Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database. Cancer Med 8(14):6243\u20136249","journal-title":"Cancer Med"},{"key":"8223_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.36468\/pharmaceutical-sciences.567","volume":"81","author":"G Kandasamy","year":"2019","unstructured":"Kandasamy G, Sivanandy P, Khobrani M et al (2019) Effectiveness of antiemetics in the management of chemotherapy-induced nausea and vomiting in cancer patients following chemotherapy guidelines. Indian J Pharm Sci 81:757\u2013765","journal-title":"Indian J Pharm Sci"},{"key":"8223_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","volume":"722","author":"K Jordan","year":"2014","unstructured":"Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197\u2013202","journal-title":"Eur J Pharmacol"},{"key":"8223_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.currproblcancer.2018.09.002","volume":"43","author":"M Araz","year":"2019","unstructured":"Araz M, Karaagac M, Korkmaz L et al (2019) The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group. Curr Probl cancer 43:344\u2013353","journal-title":"Curr Probl cancer"},{"key":"8223_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00520-003-0553-6","volume":"12","author":"F Roila","year":"2004","unstructured":"Roila F (2004) Transferring scientific evidence to oncological practice: a trial of three different implementation strategies on antiemetic prescriptions. Support Care Cancer 12:446\u2013453","journal-title":"Support Care Cancer"},{"key":"8223_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.6004\/jnccn.2009.0040","volume":"7","author":"SM Grunberg","year":"2009","unstructured":"Grunberg SM (2009) Obstacles to the Implementation of Antiemetic Guidelines. J Natl Compr Canc Netw 7:601\u2013605","journal-title":"J Natl Compr Canc Netw"},{"key":"8223_CR19","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00520-014-2136-0","volume":"22","author":"ML Affronti","year":"2014","unstructured":"Affronti ML, Schneider SM, Herndon JE et al (2014) Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence in to practice. Support Care Cancer 22:1897\u20131905","journal-title":"Support Care Cancer"},{"key":"8223_CR20","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.21873\/anticanres.15154","volume":"41","author":"K Ohata","year":"2021","unstructured":"Ohata K, Fujii H, Sadaka S et al (2021) Comparison of chemotherapy-induced nausea and vomiting between gemcitabine plus nab-paclitaxel combination chemotherapy and gemcitabine monotherapy in patients with advanced pancreatic cancer. Anticaner Res 41:3643\u20133648","journal-title":"Anticaner Res"},{"key":"8223_CR21","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s12094-016-1583-0","volume":"18","author":"R De las Pe\u00f1as","year":"2016","unstructured":"De las Pe\u00f1as R, Blasco A, De Castro J et al (2016) SEOM clinical guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016). Clin Transl Oncol 18:1237\u20131242","journal-title":"Clin Transl Oncol"},{"key":"8223_CR22","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","volume":"24","author":"Y Okada","year":"2019","unstructured":"Okada Y, Oba K, Furukawa N et al (2019) One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. Oncologist 24:1593\u20131600","journal-title":"Oncologist"},{"key":"8223_CR23","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1007\/s00520-012-1527-3","volume":"20","author":"PJ Hesketh","year":"2021","unstructured":"Hesketh PJ, Morrow G, Aw K et al (2021) Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC). Support Care Cancer 20:2633\u20132637","journal-title":"Support Care Cancer"},{"key":"8223_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00432-013-1540-z","volume":"140","author":"S Vig","year":"2014","unstructured":"Vig S, Siebert L, Green MR (2014) Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity. J Cancer Res Clin Oncol 140:77\u201382","journal-title":"J Cancer Res Clin Oncol"},{"key":"8223_CR25","unstructured":"Dranitsaris G, Joy A, Young SD, Clemons M, Callaghan W, Petrella T (2009) Identifying patients at high risk of nausea and vomiting after chemotherapy. The development of a practical predicting tool I. Acute nausea and vomiting. J Support Oncol 7"},{"key":"8223_CR26","unstructured":"Petrella T, Clemons M, Joy A, Young S, Callaghan W, Dranitsaris G (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool II. Delayed nausea and vomiting. J Support Oncol 7"},{"key":"8223_CR27","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s00520-017-3679-7","volume":"25","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Shimokawa M, Miyoshi T et al (2017) A prospective, observational, multicentre study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. Support Care Cancer 25:2707\u20132714","journal-title":"Support Care Cancer"},{"key":"8223_CR28","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.21037\/apm-19-453","volume":"10","author":"T Smit","year":"2021","unstructured":"Smit T, Kotze I, du Plessis J (2021) The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy. Ann Palliat Med 10:2679\u20132686","journal-title":"Ann Palliat Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08223-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08223-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08223-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T15:06:47Z","timestamp":1705417607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08223-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["8223"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08223-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"1 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Schwartzberg COI: Consultant, Helsinn, GlaxoSmithKline, Pfizer.The other authors have no relevant financial or non-financial interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"37"}}